Results 1 to 10 of about 286,663 (309)

IDO1 Promotes the Progression of NSCLC by Regulating the Polarization of M2 Macrophages

International Journal of General Medicine, 2023
Xiao Chen,1,2 Jie Yao,1 Meng-Yu Zhang,1 Rui Li,1 Xiao Liu,1 Yi-Qing Qu1 1Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, People’s Republic of China; 2Department of Respiratory Medicine, Tai’an City Central
Chen X, Yao J, Zhang MY, Li R, Liu X, Qu YQ   +5 more
doaj   +1 more source

Pattern of care in locally advanced non-small cell lung cancer: A tertiary care experience from India

Lung India
Introduction and Objective: Heterogeneity in locally advanced (LA) Non-Small Cell Lung Cancer (NSCLC) group necessitates a multi-disciplinary approach to its management. Surgery is the standard of care treatment if resectable; otherwise, concurrent chemo-
Aswin Ravi, Sushmita Pathy, Supriya Mallick, Prabhat S. Malik, Sunil Kumar, Rajeev Kumar   +5 more
doaj   +1 more source

Long Noncoding RNA LINC01426 Sequesters microRNA-519d-5p to Promote Non-Small Cell Lung Cancer Progression by Increasing ETS1 Expression [Retraction]

Cancer Management and Research, 2023
Dai J, Wang B, Zhao Y, et al. Cancer Manag Res. 2020;12:12697–12708. At the authors request, the Editor and Publisher of Cancer Management and Research wish to retract the published article.
Dai J, Wang B, Zhao Y, Zuo X, Cui H, Chen X, Liu X   +6 more
doaj  

Hydroxygenkwanin Suppresses Non-Small Cell Lung Cancer Progression by Enhancing EGFR Degradation

Molecules, 2020
Epidermal growth factor receptor (EGFR) is frequently overexpressed and mutated in non-small cell lung cancer (NSCLC), which is the major type of lung cancer.
Yann-Lii Leu, Tong-Hong Wang, Chih-Ching Wu, Kuo-Yen Huang, Yu-Wen Jiang, Yi-Chiung Hsu, Chi-Yuan Chen   +6 more
doaj   +1 more source

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan

Asian Pacific Journal of Cancer Biology, 2021
Introduction: The preferred first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive (EGFRm) advanced/metastatic non-small lung cancer (NSCLC) are EGFR-tyrosine kinase inhibitors (TKIs).
Jae Cheol Lee, Jen-Yu Hung, Young-Chul Kim, Gee-Chen Chang, Seung Soo Yoo, Sheng-Hsiung Yang, Keith L Davis, Saurabh P Nagar, Aliki Taylor, Sung Yong Lee, Jin-Yuan Shih   +10 more
doaj   +1 more source

ADH5 inhibits proliferation but promotes EMT in non-small cell lung cancer cell through activating Smad2/Smad3

Open Life Sciences
Cell proliferation and epithelial–mesenchymal transition (EMT) are two common tumor phenotypes closely linked to malignant tumor progression. Genes regulating tumor progression often exhibit consistent regulatory trends in these phenotypes; however ...
Tan Xinyu, Huang Ye, Li Xiaolei, Xu Fei, Xu Xinping   +4 more
doaj   +1 more source

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

Медицинский совет, 2019
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily.
K. K. Laktionov, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov, D. T. Marinov, D. A. Peregudov, M. S. Ardzinba   +7 more
doaj   +1 more source

Long Noncoding RNA SNHG7 Accelerates Proliferation, Migration and Invasion of Non-Small Cell Lung Cancer Cells by Suppressing miR-181a-5p Through AKT/mTOR Signaling Pathway

Cancer Management and Research, 2020
Liping Li, Dan Ye, Liang Liu, Xiaoju Li, Jun Liu, Shengtian Su, Wenjing Lu, Zhigao Yu Department of Oncology, Xiantao First People’s Hospital, Xiantao, Hubei, People’s Republic of ChinaCorrespondence: Zhigao YuDepartment of Oncology, Xiantao ...
Li L, Ye D, Liu L, Li X, Liu J, Su S, Lu W, Yu Z   +7 more
doaj  

IL-33 Promotes the Growth of Non-Small Cell Lung Cancer Cells Through Regulating miR-128-3p/CDIP1 Signalling Pathway [Corrigendum]

Cancer Management and Research, 2021
Zhou X, Feng Y, Liu S, et al. Cancer Manag Res. 2021;13:2379–2388. The authors have advised that the funding statement on page 2387 is incorrect.
Zhou X, Feng Y, Liu S, Li C, Teng Y, Li X, Lu J   +6 more
doaj  

GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC

International Journal of General Medicine, 2023
Honghong Fan,* Yuxin Shi,* Huiyu Wang, Yuting Li, Jie Mei, Junying Xu, Chaoying Liu Department of Oncology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214023, People’s Republic of China*These authors ...
Fan H, Shi Y, Wang H, Li Y, Mei J, Xu J, Liu C   +6 more
doaj